325 related articles for article (PubMed ID: 23424288)
21. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
22. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study.
Arfè A; Scotti L; Varas-Lorenzo C; Nicotra F; Zambon A; Kollhorst B; Schink T; Garbe E; Herings R; Straatman H; Schade R; Villa M; Lucchi S; Valkhoff V; Romio S; Thiessard F; Schuemie M; Pariente A; Sturkenboom M; Corrao G;
BMJ; 2016 Sep; 354():i4857. PubMed ID: 27682515
[TBL] [Abstract][Full Text] [Related]
23. [Cardiovascular safety of non-steroidal anti-inflammatory drugs].
Møllersen MV; Norgård H; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2015 Mar; 135(6):542-6. PubMed ID: 25806762
[TBL] [Abstract][Full Text] [Related]
24. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.
Conaghan PG
Rheumatol Int; 2012 Jun; 32(6):1491-502. PubMed ID: 22193214
[TBL] [Abstract][Full Text] [Related]
25. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.
Bazargani YT; Ugurlu M; de Boer A; Leufkens HGM; Mantel-Teeuwisse AK
BMC Cardiovasc Disord; 2018 Jun; 18(1):126. PubMed ID: 29940880
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular risk of non-steroidal anti-inflammatory drugs.
Alušík Š; Paluch Z
Vnitr Lek; 2018; 64(3):266-271. PubMed ID: 29766729
[TBL] [Abstract][Full Text] [Related]
27. [Risk of fatal/non-fatal events in patients with previous coronary heart disease/acute myocardial infarction and treatment with non-steroidal anti-inflammatory drugs].
Muñoz Olmo L; Juan Armas J; Gomariz García JJ
Semergen; 2018; 44(5):355-363. PubMed ID: 28882733
[TBL] [Abstract][Full Text] [Related]
28. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG;
BMJ; 2009 Jul; 339():b2538. PubMed ID: 19602530
[TBL] [Abstract][Full Text] [Related]
31. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.
Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC
Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025
[TBL] [Abstract][Full Text] [Related]
32. RETRACTED: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis.
da Costa BR; Reichenbach S; Keller N; Nartey L; Wandel S; Jüni P; Trelle S
Lancet; 2016 May; 387(10033):2093-2105. PubMed ID: 26997557
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
34. [What do we know about the cardiovascular toxicity of the NSAIDs?].
Sibilia J; Deray G; Montalescot G
Presse Med; 2006 Sep; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
[TBL] [Abstract][Full Text] [Related]
35. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
36. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies.
Varas-Lorenzo C; Riera-Guardia N; Calingaert B; Castellsague J; Salvo F; Nicotra F; Sturkenboom M; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):559-70. PubMed ID: 23616423
[TBL] [Abstract][Full Text] [Related]
37. Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
Moore N
Drug Saf; 2020 Apr; 43(4):301-318. PubMed ID: 31916080
[TBL] [Abstract][Full Text] [Related]
38. Remove diclofenac from lists of essential drugs.
BMJ; 2013 Feb; 346():f1053. PubMed ID: 23427127
[No Abstract] [Full Text] [Related]
39. Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study.
Bonnesen K; Pedersen L; Ehrenstein V; Grønkjær MS; Sørensen HT; Hallas J; Lash TL; Schmidt M
Drug Saf; 2023 Jun; 46(6):533-543. PubMed ID: 37131013
[TBL] [Abstract][Full Text] [Related]
40. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Prozzi GR; Cañás M; Urtasun MA; Buschiazzo HO; Dorati CM; Mordujovich-Buschiazzo P
Medicina (B Aires); 2018; 78(5):349-355. PubMed ID: 30285927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
